On 19 and 20 June, the 3rd National Congress of the Ispor Roma for Future GIRF group was held in Bologna, confirming its role as a reference event for young professionals working in the health sector.
Pharma Value participated with 2 scientific contributions.
- Poster 'Comparators for rare disease drugs in P&R evaluations in Italy
By Federico Tartarelli and Valeria Viola, in collaboration with Ilaria Ciancaleoni Bartoli, Francesco Macchia, Roberta Venturi of Rarelab.
The aim of this paper is to highlight the problems and difficulties related to drugs for rare diseases during the negotiation process, particularly with regard to the use of comparators.
- Poster 'FDA vs EMA: comparative analysis in the approval of new chemical entities' by Olivia Ramdin, Valeria Viola, Ginevra Mastroianni and Federico Tartarelli
The analysis was conducted with the aim of identifying variables that may condition approvals of new entities
chemicals.
Valeria Viola, together with Marcello Girardini, Market Access Manager, Pierre Fabre Pharma, moderated the Round table within 'SESSION IV - Impact of the European HTA-R on Local Medicines Processes and Decisions' .
Participants included: Claudia Cardone, Medical Oncologist at IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli; Elisa Crovato, Pricing & Market Access Director, Chiesi Italia; Eugenio Di Brino, Co-Founder & Partner, Altems Advisory; Matteo Ferrario, Precision Medicine, Specialty & Rare Conditions Access Lead, Roche; Simona Montilla, Dirigente Farmacista, Agenzia Italiana del Farmaco (AIFA) and Teresa Petrangolini, Director of the Patient Advocacy Lab ALTEMS.
The debate gave rise to many interesting considerations.
The Health Technology Assessment (HTA) regulation represents an important pact of solidarity between the countries of the European Union, aimed at promoting collaboration and coordination in the evaluation of drug efficacy and safety. This joint approach enables the sharing of knowledge and resources, allowing even countries with less developed infrastructures to benefit from high quality assessments.
During a recent period characterised by dynamism and challenges, the aim of creating a 'friendly space' to gather needs and foster discussion between various representatives, including the Italian regulatory agency, clinicians, patient associations, pharmaceutical companies and academia, was reaffirmed.
Stakeholders expressed optimism towards the HTA-R, recognising that despite the currently unpredictable scenarios, there will be an initial learning curve.
For young pharmaceutical professionals, HTA-R represents an opportunity to master the basics of an already well-established multidisciplinary process. The ISPOR Italy - Rome Chapter can serve as a facilitating platform for this training.
Pharma Value has decided to sponsor, with a non-conditional contribution, the 3rd GIRF Conference once again demonstrating its commitment to the empowerment of the younger generation in the pharmaceutical and healthcare world.
We deeply believe in the importance of dedicating time and resources to give young people a voice, space, visibility and decision-making power. Supporting them means having competent people in companies, institutions and places of care. We hope that our support will help young people develop not only technical skills, but also the awareness that their opinion matters and that they are responsible for their actions: the decisions they make will have a short and medium-term impact on their lives and on the country.
Congratulations to Pietro Brambilla and Giorgio Casilli, Presidents of the 3rd Congress, a special thanks goes to Andrea Marcellusi, President of ISPOR Italy - Rome Chapter.
Pharma Value had already participated in last year's 2nd GIRF Congress with an analysis entitled "Regional access times in Italy. What makes the difference in speed and equity of access?".
